Desde el diagnóstico bioquímico al diagnóstico clínico | 18 JUN 19

Manifestaciones cutáneas de la resistencia a la insulina

La resistencia a la insulina es una característica bioquímica patognomónica de la obesidad y la diabetes. Sus manifestaciones cutáneas ofrecen una manera fiable y fácil de detectarla
Autor/a: González-Saldivar G, Rodríguez-Gutiérrez R . Ocampo-Candiani J . Dermatol Ther (Heidelb) (2017) 7:37–51
INDICE:  1. Página 1 | 2. Página 1
Página 1
Referencias bibliográficas: 

1. Boyle J, Thompson T, Gregg E, Barker L, Williamson D. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr. 2010;8:1.

2. Moller DE, Flier JS. Insulin resistance— mechanisms, syndromes, and implications. N Engl J Med. 1991;325:938–48.

3. Jung U, Choi M-S. Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci. 2014;15:6184–223. 4. Napolitano M, Megna M, Monfrecola G. Insulin resistance and skin diseases. Sci World J. 2015. doi:10.1159/000245731.

5. Yamazaki H, Ito S, Yoshida H. Acanthosis nigricans is a reliable cutaneous marker of insulin resistance in obese Japanese children. Pediatr Int. 2003;45:701–5.

6. Mukhtar Q, Cleverley G, Voorhees RE, McGrath JW. Prevalence of acanthosis nigricans and its association with hyperinsulinemia in New Mexico adolescents. J Adolesc Health. 2001;28:372–6.

7. Edgerton DS, et al. Insulin’ s direct effects on the liver dominate the control of hepatic glucose production. J Clin Invest. 2006;116:521–7.

8. Shanik MH, et al. Insulin resistance and hyperinsulinemia: Is hyperinsulinemia the cart or the horse? Diabet Care. 2008;31:262–8.

9. Hermanns-Leˆ T, Scheen A, Pie´rard GE. Acanthosis nigricans associated with insulin resistance. Am J Clon Dermatol. 2004;5:199–203.

10. Yosipovitch G, DeVore A, Dawn A. Obesity and the skin: skin physiology and skin manifestations of obesity. J Am Acad Dermatol. 2007;56:901–16.

11. Barbato M, et al. Association of acanthosis nigricans and skin tags with insulin resistance. An Bras Dermatol. 2012;87:97–104.

12. Cordain L, Eades MR, Eades MD. Hyperinsulinemic diseases of civilization: more than just Syndrome X. Comp Biochem Physiol A Mol Integr Physiol. 2003;136:95–112.

13. Murphy-Chutorian B, Han G, Cohen SR. Dermatologic manifestations of diabetes mellitus. a review. Endocrinol Metab Clin N Am. 2013;42:869–98.

14. El Safoury OS, Ibrahim M. A clinical evaluation of skin tags in relation to obesity, type 2 diabetis mellitus, age, and sex. Indian J Dermatol. 2011;56:393–7. 15. Sari R, Akman A, Alpsoy E, Balci MK. The metabolic profile in patients with skin tags. Clin Exp Med. 2010;10:193–7.

16. Rasi A, Soltani-Arabshahi R, Shahbazi N. Skin tag as a cutaneous marker for impaired carbohydrate metabolism: a case–control study. Int J Dermatol. 2007;46:1155–9.

17. Demir S, Demir Y. Acrochordon and impaired carbohydrate metabolism. Acta Diabetol. 2002;39:57–9.

18. Schilling WH, Crook MA. Cutaneous stigmata associated with insulin resistance and increased cardiovascular risk. Int J Dermatol. 2014;53:1062–9.

19. Margolis J, Margolis LS. Skin tags-a frequent sign of diabetes mellitus. N Engl J Med. 1976;294:1184.

20. Kahana M, et al. Skin tags: a cutaneous marker for diabetes mellitus. Acta Derm Venereol. 1987;67:175–7.

21. Behm B, Schreml S, Landthaler M, Babilas P. Skin signs in diabetes mellitus. J Eur Acad Dermatol Venereol. 2012;26:1203–11.

22. Men J, Boberg J. Fibroepithelial polyps. An unusual case report. J Am Podiatr Med Assoc. 1990;80:496–8.

23. Kamino H, Reddy VB, Pui J. Dermatology. Philadelphia: Elsevier; 2012. p. 1961.

24. Brinster NK, Liu V, Diwan AH, McKee PH. Dermatopathology: high-yield pathology. Edinburgh: Elsevier; 2011. p. 446.

25. Pfenninger JL. Pfenninger and Fowler’s Procedures for Primary Care. Philadelphia: Elsevier; 2011. p. 69–84.

26. Sinha S, Schwartz RA. Juvenile acanthosis nigricans. J Am Acad Dermatol. 2007;57:502–8.

27. Dobrev D. Case of acanthosis nigricans associated with gastric cancer. Suvr Med. 1958;9:100–3.

28. Lindewall G. Acanthosis nigricans associated with carcinoma of the stomach: a case report. Acta Derm Venereol. 1960;40:493–9.

29. Pollitzer S. Acanthosis nigricans: a symptom of a disorder of the abdominal sympathetic. JAMA. 1909;53:1369–73.

30. Janovsky V. Acanthosis nigricans. In: Unna PG, Morris M, Besnier E, editors. International atlas of rare skin diseases. London: HK Lewis & Co; 1891. p. 4–5.

31. Burke JP, Hale DE, Hazuda HP, Stern MP. A quantitative scale of acanthosis nigricans. Diabet Care. 1999;22:1655–9.

32. Go´mez-Flores M, et al. Implications of a clinically ignored site of acanthosis nigricans: the knuckles. Exp Clin Endocrinol Diabet. 2014;123:27–33.

33. Kluczynik C, et al. Acanthosis nigricans and insulin resistance in overweight children and adolescents. An Bras Dermatol. 2012;87:531–7.

34. Stuart CA, Pate CJ, Peters EJ. Prevalence of acanthosis nigricans in an unselected population. Am J Med. 1989;87:269–72.

35. Mun˜oz-Pe´rez MA, Camacho F. Acanthosis nigricans: a new cutaneous sign in severe atopic dermatitis and Down syndrome. J Eur Acad Dermatol Venereol. 2001;15:325–7.

36. Kong AS, et al. Acanthosis nigricans and diabetes risk factors: prevalence in young persons seen in Southwestern US primary care practices. Ann Fam Med. 2007;5:202–8.

37. Matsuoka LY, Wortsman J, Goldman J. Acanthosis Nigricans. Clin Dermatol. 1993;11:21–5.

38. Puri N. A study of pathogenesis of acanthosis nigricans and its clinical implications. Indian J Dermatol. 2011;56:678–83.



Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

Términos y condiciones de uso | Política de privacidad | Todos los derechos reservados | Copyright 1997-2024